Free tool
FAERS Monitor: Pliaglis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021717 or its brand name (Pliaglis, Lidocaine, Tetracaine). Reports on generic versions are filed under their own applications.
Reports
45
Serious
23
51% of reports
Hospitalization
5
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- erythema22
- swelling face9
- pruritus8
- skin burning sensation5
- angioedema3
- blister3
- dizziness3
- drug ineffective3
- eyelid oedema3
- skin swelling3
- somnolence3
- application site erythema2
- deformity2
- feeling hot2
- headache2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 4 |
| 2014 | 16 |
| 2015 | 9 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skin swellingSignal | 3 | 161.6 | 54.2 | 332 |
| eyelid oedemaSignal | 3 | 120.7 | 40.4 | 246 |
| deformity | 2 | 100.0 | 25.8 | 110 |
| swelling faceSignal | 9 | 64.6 | 36.0 | 503 |
| erythemaSignal | 22 | 50.0 | 37.1 | 1,018 |
| application site erythema | 2 | 35.7 | 9.2 | 37 |
| skin burning sensationSignal | 5 | 32.6 | 14.3 | 124 |
| angioedemaSignal | 3 | 31.7 | 10.6 | 61 |
| blisterSignal | 3 | 25.0 | 8.4 | 47 |
| feeling hot | 2 | 15.2 | 3.9 | 14 |
| pruritusSignal | 8 | 9.7 | 5.2 | 55 |
| somnolenceSignal | 3 | 7.0 | 2.3 | 10 |
| dizziness | 3 | 2.8 | 0.9 | 2 |
| headache | 2 | 1.5 | 0.4 | 0 |
| drug ineffective | 3 | 1.1 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.